According to the Market Statsville Group (MSG), the Global small molecule targeted cancer therapy Market was valued at USD 83,410 million in 2023 and is expected to grow from USD 91,333 million in 2024 to USD 1,88,780 million by 2033, by exhibiting a CAGR of 9.50 % during the forecast period (2024-2033)
Small-Molecule Targeted Cancer Therapy is a form of cancer therapy in which small molecules target and inhibit the proliferation of cancerous cells. In contrast to chemotherapy, wherein bad and good cells are damaged, targeted therapies by small molecules typically cut off specific molecular pathways that are used in the survival and growth of cancer cells. These therapies generally work to inhibit tumor growth and modulate the immune response, provide an added side effect reduction. The increasing incidence of cancers globally is one of the major forces driving the market. It was estimated by the World Health Organization that in the year 2020, cancer would be one of the leading causes of approximately 19.3 million new cases and 10 million deaths per year. New targets and innovative treatments are being pursued through ongoing research and developments in molecular biology and genetics. Personalized medicine, which has become a growing concept tailored to specific treatment strategies according to individual genetic profiles, is increasingly applied.
Furthermore, Small molecule therapies are integral to this approach because of the specificity towards molecular alterations in cancer cells. The trend in personalized medicine has hastened the development of therapies tailored to individual genetic profiles. This strategy improves small molecule therapies through the better efficiency of their actions and limits adverse effects. This approach of targeting combination with other types of treatments, such as immunotherapy or chemotherapy, has now come out as a mainstream strategy for optimizing the outcome of treatment and countering drug resistance. Since new targets are to be discovered and novel small molecule therapies will be developed, continuous R&D is necessary. Forging ahead comes from progress in genomics, proteomics, and molecular biology. The landscape of regulatory aspects of small-molecule targeted therapies is in flux and witnessed an increase in approvals of the new drugs and indications. Policies for market access and reimbursement also pose a very significant hurdle for adoption in their territories.
Request Sample Copy of this Report: https://www.marketstatsville.com/request-sample/small-molecule-targeted-cancer-therapy-market?utm_source=free&utm_medium=harsh
Scope of the Small Molecule Targeted Cancer Therapy Market
The study categorizes the small molecule targeted cancer therapy market based on drug type, cancer type, route of administration, and end-user area at the regional and global levels.
By Drug Type Outlook (Sales, USD Million, 2019-2033)
- Tyrosine Kinase Inhibitors (TKIs)
- Proteasome Inhibitors
- BRAF Inhibitors
- Other Targeted Therapies
By Cancer Type Outlook (Sales, USD Million, 2019-2033)
- Lung Cancer
- Breast Cancer
- Leukemia and Lymphomas
- Melanoma
- Others
By Route of Administration Outlook (Sales, USD Million, 2019-2033)
- Oral
- Injectable
By End User Outlook (Sales, USD Million, 2019-2033)
- Hospitals
- Specialty Clinics
- Research Institutions
By Region Outlook (Sales, USD Million, 2019-2033)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- Italy
- France
- UK
- Spain
- Poland
- Russia
- The Netherlands
- Norway
- Czech Republic
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Indonesia
- Malaysia
- Thailand
- Singapore
- Australia & New Zealand
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Rest of South America
- The Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Northern Africa
- Rest of MEA
Direct Purchase Report: https://www.marketstatsville.com/buy-now/small-molecule-targeted-cancer-therapy-market?opt=3338&utm_source=free&utm_medium=harsh
Targeted Therapies segment accounts for the largest market share by Drug Type
Based on the drug type, Small molecule targeted therapies are greatly used depending on the nature of the drug, especially in NSCLC patients with certain genetic mutations. As an example, drugs under EGFR Inhibitors include erlotinib and gefitinib - drugs that target mutations in the epidermal growth factor receptor (EGFR) gene, which generally occur in NSCLC patients. ALK Inhibitors are Crizotinib (Xalkori) targets rearrangements in the ALK gene, a mutation present in some percent of NSCLC patients. Lung cancer is the most common of any cancer type worldwide. The International Agency for Research on Cancer (IARC) estimated new cases of lung cancer to amount to 2.2 million globally in 2020.
Although less common than their counterpart targeted therapies are being developed for SCLC, especially as scientists continue to unravel the molecular underpinnings of this cancer type. For HER2-positive breast cancer, small-molecule targeted therapies are an important part of the treatment. Drugs such as lapatinib (Tykerb) and neratinib (Nerlynx) disrupt HER2 signaling. They are generally used in conjunction with other therapies to treat this very aggressive subtype. Research still goes on to pinpoint what the more precise targets of TNBC, which has no estrogen progesterone, or HER2 receptors, are. Breast cancer is the leading diagnosis and cause of death due to cancer in women. Of 2.3 million new cases diagnosed worldwide, in 2020, as established by the World Health Organization.
North America accounted for the largest market share by Region.
Based on the regions, High incidence rates of cancer, well-established infrastructures in health care, and a strong investment in research and development are the factors driving the U.S. region. Advanced healthcare infrastructure and well-established healthcare systems characterize North America, especially the United States and Canada. Smooth approval processes through the FDA in the U.S. and Health Canada for innovative therapies are further expanding the market. Heavy incidence of cancer, particularly lung, breast, and colorectal cancers, motivates the requirements for targeted therapies.
Competitive Landscape: Small Molecule Targeted Cancer Therapy Market
Small Molecule Targeted Cancer Therapy Market The market of small molecule targeted cancer therapy is one of the huge competitors and highly competitive in the market. It adopts the strategies, such as partnerships, product launches, acquisitions, agreements, and growth, to boost its position in the market. Most sectors of businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.
Major players in the small molecule targeted cancer therapy market are:
- Pfizer Inc.
- Abbott Laboratories
- Novartis AG
- OncoGenex Pharmaceuticals, Inc.
- Bristol-Myers Squibb Company
- Cytokinetics Inc.
- Roche Holding AG
- GlaxoSmithKline plc
- Eli Lilly
- Boehringer Ingelheim GmbH
- Amgen Inc.
- Bayer HealthCare AG
- Hospira Inc.
- AstraZeneca
- AVEO Pharmaceuticals, Inc.
- Johnson & Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd.
- Allergan
- Merck Sharp & Dohme Corp.
- Gilead Sciences, Inc.
- Sanofi
- Bausch Health
Request For Report TOC: https://www.marketstatsville.com/table-of-content/small-molecule-targeted-cancer-therapy-market
Recent Development
- In April 2024, Pfizer Inc., highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago. More than 50 abstracts, including 11 oral presentations, will be presented from Pfizer’s broadened portfolio of approved and pipeline therapies across the company’s key tumor areas and core scientific modalities, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies.
- In February 2024, Roche Tissue Diagnostics entered into an exclusive deal with PathAI to co-develop AI algorithms that will improve the precision of medicine and expand patient access to targeted treatments. The algorithms will be integrated into Roche's Navify Digital Pathology platform, which all pathology labs use.
Comments
0 comment